Latest news

• Roche moving closer to approval of Spark takeover; report

  neparvovec) for a rare inherited retinal disease – as well as four other candidates in clinical trials headed by haemophilia A therapy SPK-8011.

• Roche buys gene therapy specialist Spark for $4.3bn

  The $114.50 per share deal will give the Swiss pharma giant rights the approved therapy Luxturna (voretigene neparvovec) for a rare inherited retinal disease, as well as four candidates in ... Also in Spark’s pipeline is SPK-7001 for choroideremia in

• J&J bolsters gene therapy unit with $100m MeiraGTx deal

  The companies will also work together on new targets for other inherited retinal diseases and on adeno-associated virus (AAV) manufacturing technology. ... The US market developed a little later, with Spark Therapeutics’ Luxturna (voretigene neparvovec

• Freeline raises £88m to accelerate haemophilia gene therapy

  additional testing of its lead haemophilia B gene therapy, and take another for Fabry disease into the clinic. ... This adds to Freeline and its focus on chronic systemic disease, Nightstar ( specialising in inherited retinal diseases), and Gyroscope,

• Novartis negotiates ex-US rights to Spark gene therapy

  Luxturna is the first gene therapy to be approved in the US where it has a similar indication - biallelic RPE65-mediated inherited retinal disease (IRD) - and is being launched at a ... No otherwise healthy child should have to go blind due to this